Quinapril and Hydrochlorothiazide |
Accuretic; Quinaretic |
Clinical Trial: Irbesartan in the Treatment of Hypertensive Patients with Metabolic Syndrome
This study is not yet open for patient recruitment.
|
Purpose
The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Metabolic Syndrome X Hypertension | Drug: irbesartan Drug: hydrochlorothiazide | Phase IV |
MedlinePlus related topics: High Blood Pressure; Metabolic Syndrome X
Study Type: Interventional
Study Design: Treatment
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Subjects must be willing and able to provide written informed consent. Subjects must read, sign, and receive a copy of the informed consent prior to any study procedures, including withdrawal of any antihypertensive medication.
- Males and females >= 18 years of age.
- Uncontrolled hypertension defined as an average systolic blood pressure >= 140 mmHg and/or an average diastolic blood pressure >= 90 mmHg. This applies to both people not taking any blood pressure medications and people taking just one blood pressure medication.
- Presenting at least 2 of the following: * Obesity; * High triglycerides; * Low HDL cholesterol; * Elevated fasting glucose.
Exclusion Criteria:
- Women of child bearing potential who are not using adequate birth control.
- Women who are pregnant or breastfeeding
- Diabetics
- Systolic blood pressure >= 180 mmHg.
- Diastolic blood pressure >= 110 mmHg.
- Stroke within past 12 months.
- Myocardial infarction and heart revascularization procedure or acute angina within past 6 months.
- Moderate to severe heart failure.
- Significant kidney or liver disease.
- Cancer in past 5 years.
- Drug or alcohol abuse.
Location and Contact Information
BMS Call Center Outside the US and Canada 1-215-347-4079 Ext. 164
More Information
Record last reviewed: May 2005
Last Updated: May 9, 2005
Record first received: May 9, 2005
ClinicalTrials.gov Identifier: NCT00110422
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-05-17
Source: ClinicalTrials.gov
Cache Date: May 18, 2005
Resources
- Accuretic (Drug Digest)
- Quinapril and Hydrochlorothiazide (Drug Digest)

Not Signed In -

